Amsino Expands North American Operations with MedXL Acquisition to Enhance Manufacturing Capacity

Amsino's Strategic Acquisition of MedXL Inc.

Amsino International Inc. has taken a significant leap in expanding its presence in the North American market with the acquisition of MedXL Inc., along with Liebel-Flarsheim Canada Inc., finalized on November 25, 2024. This transaction not only represents a remarkable step forward for Amsino but also doubles its manufacturing capacity, positioning the company to better serve its customer base across North America.

Overview of MedXL's Capabilities

Founded in 1992, MedXL is recognized as a premier Canadian manufacturer specializing in medical devices, particularly in the domain of drug delivery systems. Their product lineup predominantly features prefilled syringes utilized in intravenous drug therapies. MedXL operates out of two cutting-edge manufacturing facilities in Quebec, complete with high-speed production lines and a dedicated distribution center. Furthermore, the facilities are fully compliant with regulatory certifications from the FDA and Health Canada, ensuring they meet the rigorous standards required in the medical sector.

The acquisition not only includes physical assets but also encompasses a wealth of intellectual property and global product registrations across approximately 60 countries. This strategic move allows Amsino to integrate new products, such as the Praxiject™ 0.9% sodium chloride injection USP prefilled syringes and CitraFlow™ range, enhancing its existing portfolio and presenting new solutions to healthcare providers.

Statement from Leadership

Dr. Richard Lee, Chairman and CEO of Amsino, expressed enthusiasm regarding the acquisition, stating, "This aligns perfectly with our reshoring strategy, allowing us to expand our manufacturing footprint and better serve customers in North America. Given today's geopolitical environment, onshore manufacturing is increasingly vital for supply chain resiliency." He emphasized the positive impact this acquisition will have on addressing the industry's current challenges.

Furthermore, Amsino's North America President, Jeff Reid, highlighted the immediate benefits of the acquisition, revealing that it will result in a combined annual manufacturing capacity exceeding 500 million units. This positions Amsino to meet increasing demands while enhancing operational efficiencies.

Synergy and Future Outlook

The merger not only integrates MedXL's manufacturing capabilities but also its product portfolio, paving the way for new synergies. Paul Parisien, President of MedXL, noted the potential for enhanced collaboration, stating, "We see strong alignment between MedXL's offerings and Amsino's strategic objectives. We are excited to work together through a seamless integration process that will enhance both organizations’ capabilities moving forward."

By acquiring MedXL, Amsino not only fortifies its market position but also demonstrates a commitment to innovation in the healthcare sector, addressing the pressing challenges of infection control and patient safety through advanced medical products. As the integration phase unfolds, industry stakeholders and healthcare providers alike watch closely, anticipating the enhanced solutions Amsino will bring to the market.

About Amsino International, Inc.

Established in 1993, Amsino International is dedicated to improving patient care through the development and manufacturing of a wide range of medical devices. With multiple FDA-registered facilities across North America and Asia, Amsino adheres to the stringent ISO 13485 quality management system, ensuring the highest standards in product safety and efficacy. For more details on their offerings, visit www.amsino.com.